August 2011

Contents

Editorial

• Volume 12 Number 7/8 July/August 2011

Special reports

• HTB supplement: 2011 pipeline report

Conference reports

• 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention 17-–20 July 2011, Rome

• Webcasts for major research at IAS

• Treatment is prevention: ARV treatment in HPTN-052 reduces transmission by at least 96%: single transmission in treatment arm occurred before viral suppression

• Daily oral tenofovir/FTC PrEP reduces heterosexual transmission by 63% in the TDF2 study

• Tenofovir/FTC vs tenofovir as daily oral PrEP: preliminary results from Partners PrEP

• Elvitegravir vs raltegravir: 48 week results in treatment-experienced patients

• Dolutegravir: 48 week results from phase II study in treatment-naive patients

• Lersivirine: 48 week results compared to efavirenz in phase 2 treatment-naive study

• Maraviroc plus atazanavir/r without nukes versus standard of care: 48 week results

• SPARTAC trial: treatment in primary infection for 48 weeks shows small delay in disease progression

• Hearing loss not associated with HIV in MACS and WIHS cohorts

• Pharmacokinetics of darunavir and fosamprenavir in pregnancy

• Low birth weight and preterm delivery

• Hormonal contraception and HIV transmission risk

• No difference in AIDS-free survival in children starting ART with a CD4% between 15%–24% compared to deferring until less than 15% in the PREDICT trial

• Paediatric antiretroviral pipeline: update on etravirine and maraviroc

• Prematurity not associated with early mortality in infants on ART

• More metabolic abnormalities in children receiving a PI compared to NNRTI in NEVEREST study

• Free online resource for treatment decisions without access to genotype resistance tests

• 17th Annual Conference of the British HIV Association (BHIVA) 6-8 April 2011, Bournemouth

• Treatment in seroconversion maintains HIV specific immune responses similar to long term slow progressors

• 18th Conference on Retroviruses and Opportunistic Infections (CROI) 27 February-–3 March 2011, Boston

• Monitoring treatment in resource limited settings: results from PHPT-3 and Stratall ANRS12110/ESTER trials

• DART: high rates of viral suppression after five years and a single CD4 test with a threshold of 250 cells/mm3 could reduce unnecessary switching

• Lopinavir/r monotherapy used as second-line therapy in resource-limited settings

• Treating children previously exposed to single dose nevirapine: update on IMPAACT P1060 and NEVEREST

• Lopinavir/ritonavir oral solution toxicity in neonates

• Paediatric antiretroviral pipeline: darunavir and raltegravir

• Pharmacokinetics of different rifabutin dosing strategies with lopinavir/ritonavir-based ART

• Initiation of ART during breastfeeding can induce multidrug resistance in infants

Antiretrovirals

• FDA approve new NNRTI rilpivirine (Edurant) in the US

• FDA approve new NNRTI-based fixed dose combination of rilpivirine/tenofovir/FTC (Complera) in the US

Treatment access

• Gilead signs up for Medicines Patent Pool

• FDA approval of generic ARVs

PK and drug interactions

• Interactions between multivitamins or acid reducing agents and dolutegravir (S/GSK1349572)

• Lopinavir and rifampicin interaction in HIV-positive patients

• Case report:– Cushing’s syndrome with atazanavir/ritonavir

Hepatitis coinfection

• FDA approve boceprevir (Victrelis) for HCV

• FDA approve telaprevir (Incivek) to treat hepatitis C

• FDA supplemental information about using boceprevir and telaprevir

HIV prevention and transmission

• HPTN 052 study stopped early: significant reduction in HIV transmission from early use of HIV treatment in serodifferent partners

On the web

• Treatment as prevention: online presentations

• CCR5 tropism guidelines

• UN High Level Meeting on HIV and AIDS

PDFs

• Volume 12 Number 7/8 July/August 2011 PDF